NCT05184894 is a NA clinical trial of AKI in Care Transitions (ACT) program in Acute Kidney Injury, sponsored by Mayo Clinic.

Who is sponsoring NCT05184894?

NCT05184894 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05184894?

Interventions in NCT05184894: AKI in Care Transitions (ACT) program.

What condition does NCT05184894 study?

NCT05184894 studies Acute Kidney Injury.

Is NCT05184894 still recruiting?

NCT05184894 is currently completed. Last updated 18 December 2024.

Are results published for NCT05184894?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-12-18 · How we verify

NCT05184894

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Acute Kidney Injury in Care Transitions

Completed NA Results posted Last updated 18 December 2024

What this trial tests

NA trial testing AKI in Care Transitions (ACT) program in Acute Kidney Injury in 50 participants. Completed in 31 October 2023.

Timeline

17 January 2022

Primary endpoint
31 October 2023

31 October 2023

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	50
Start date	17 January 2022
Primary completion	31 October 2023
Estimated completion	31 October 2023
Sites	1 location across United States

Drugs / interventions tested

AKI in Care Transitions (ACT) program

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Subjects to Complete the ACT Program Primary · 30 days after hospitalization

Total number of subjects to complete the full ACT program intervention

Group	Value	95% CI
AKI in Care Transitions (ACT) Group	22

Sponsor's own description

This research is being done to develop materials and processes that will help facilitate education and kidney care coordination for AKI survivors.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive Acute Kidney Injury Survivor Care: Protocol for the Randomized Acute Kidney Injury in Care Transitions Pilot Trial.
May HP, Griffin JM, Herges JR, Kashani KB, et al · · 2023 · cited 4× · PMID 37213187 · DOI 10.2196/48109
Acute Kidney Injury in Care Transitions (ACT): A Randomized Controlled Feasibility Trial.
Barreto EF, May HP, Cole KC, Griffin JM, et al · · 2025 · cited 2× · PMID 39652038 · DOI 10.1053/j.ajkd.2024.08.005
Implementing the Acute Kidney Injury in Care Transitions (ACT) Program: Results From a Mixed Methods Feasibility Study.
May HP, Ledet CB, Griffin JM, Herges JR, et al · · 2026 · PMID 41510002 · DOI 10.1016/j.xkme.2025.101178

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05184894 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 18 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05184894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing